Navigation Links
Oral drug sets a new survival standard for bone marrow cancer
Date:11/21/2007

Findings from two large, international clinical trials show "unprecedented" survival for patients with multiple myeloma, a blood cancer that occurs in the blood-making cells of bone marrow. The findings demonstrate that with Revlimid, an oral cancer drug, all measures of myeloma showed significant improvement in patients where previous treatments had failed. Rush University Medical Center took part in the U.S. study. Results of the study were published November 21 in the New England Journal of Medicine.

In the study, a total of 353 patients were enrolled at 44 centers. Of those patients, 177 were assigned to receive Revlimid (lenalidomide) plus dexamethasone, a steroid hormone, and 176 received a placebo plus dexamethasone. According to the study results, patients who received Revlimid had a median survival of 29.6 months, compared to 20.2 months for the placebo group. In the Revlimid group, 61 percent of patients responded to therapy as compared with 19.9 percent in the placebo group.

According to the International Myeloma Foundation, follow-up data from the U.S. study and a European study report even better results. Patients treated with Revlimid had a median survival of nearly three years (35 months), the longest median survival in this difficult to treat patient group.

"Myeloma, also called multiple myeloma, is of growing interest and concern," said Dr. Stephanie Gregory, the director of the section of Hematology at Rush University Medical Center. "Statistics show the number of diagnoses is increasing in the United States where most cancers are decreasing, and myeloma is being found in increasingly younger patients. These trends give us some urgency in having potent treatments to fight this disease."

Revlimid is an immunomodulatory agent, a drug that can modify or regulate the functioning of the immune system. It is the newest of what are called the novel therapies that have changed the outlook for myeloma patients. It i
'/>"/>

Contact: Kim Waterman
Kimberly_Waterman@rush.edu
312-942-7820
Rush University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
4. Human C-reactive protein regulates myeloma tumor cell growth and survival
5. Mediterranean Diet May Boost Alzheimers Survival
6. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
7. The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival
8. Communication in cancer world is key to survival
9. Molecular profiling can accurately predict survival in colon cancer patients
10. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
11. Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... ... ... March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery ... off Springer Mountain and heading north. Since that day, Phil has hiked over 1400 miles ... by friends and family. He visited CCAR and left an inspirational message to his ...
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of Nursing, ... on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. ... this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit ...
(Date:7/31/2015)... ... 31, 2015 , ... Recently touted by Becker’s Healthcare as ... analytics , Jvion continues to disrupt the predictive analytic and big data market ... and population level illness to drive prevention and better health outcomes. Most recently, ...
(Date:7/31/2015)... ... ... There’s no better way to enjoy the summer weather than by being outside ... making July the most appropriate to be National Hot Dog Month. King Kullen honors ... next cookout different than the ones in the past. Celebrate National Hot Dog Month ...
(Date:7/31/2015)... ... ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam Prep in ... The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust selection of ... easy and painless. MDLinx offers thousands of board-exam style questions and exam-specific content ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... 2011 -- A research group led by a professor from ... this week as one of the first three centers chosen ... called the Centers for Research Excellence, known in brief ... national program and will eventually include 30 research centers operating ...
... brought into hospital with alcohol-related illnesses or injuries but how ... A researcher at The University of Nottingham is launching ... student nurses are receiving the alcohol training and education which ... news that alcohol-related admissions to hospital have topped one million ...
... -- Four of the most frequently prescribed epilepsy drugs appear to ... pregnancy, a new study finds. And the higher the ... in the June 6 online edition of The Lancet Neurology ... as the choice of drug," the authors said in a journal ...
... new targeted therapy for prostate cancer halts tumor growth ... to hormone therapy, a new study finds. The results ... Annual Meeting in Boston. "This targeted therapy may ... of men with advanced, hormone-refractory prostate cancer," said lead ...
... By Amanda Gardner HealthDay Reporter , SUNDAY, ... lung cancer only take four courses of two chemotherapy drugs ... of those drugs may delay return of the deadly disease, ... but Spanish scientists report that staying on Alimta (pemextrexed) delayed ...
... at the Indiana University School of Medicine have discovered ... pain. Unlike current treatments this peptide does not ... memory loss, or depression, according to an article in ... The peptide, CBD3, has been shown in mice ...
Cached Medicine News:Health News:Group led by Hebrew University professor chosen as Israeli Center for Research Excellence 2Health News:Are frontline nurses prepared for alcohol-related cases? 2Health News:Epilepsy Drugs' Risk of Birth Defects May Be Dose-Dependent 2Health News:Epilepsy Drugs' Risk of Birth Defects May Be Dose-Dependent 3Health News:Targeted cancer therapy kills prostate tumor cells 2Health News:Taking Chemo Drug Continuously Delayed Lung Cancer's Return 2Health News:Taking Chemo Drug Continuously Delayed Lung Cancer's Return 3Health News:Indiana University neuroscientists map a new target to wipe pain away 2
(Date:7/30/2015)... International Inc. (NYSE: MTD ) today announced second ... , Sales in local currency increased 3% ... sales decreased 4% as currency reduced sales growth by ... diluted share as reported (EPS) were $2.73, compared with ... , an increase of 9% over the prior-year ...
(Date:7/30/2015)... 30, 2015  ResMed Inc. (NYSE: RMD ) ... 2015.  Revenue for the quarter was $453.1 million, a ... 30, 2014 (a 17 percent increase on a constant ... the quarter ended June 30, 2014.  Diluted earnings per ... quarter ended June 30, 2014.  The ...
(Date:7/30/2015)... -- Today we bring you a special edition of #MedicareMonday on Medicare,s 50 th ... our Medicare resources and continue highlighting the success of the prescription drug benefit, commonly ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... 4, 2007 - Molecular Insight,Pharmaceuticals, Inc. (NASDAQ: ... the results of several preclinical studies at,the ... Nuclear Medicine (SNM) in,Washington, D.C. The presentations ... clinical-stage, targeted,radiotherapeutic candidate for the treatment of ...
... ZymoGenetics,Inc. today announced that interim findings were presented ... B-cell chronic,lymphocytic leukemia (B-CLL) at the American Society ... included intravenous,administration of higher doses than had been ... was well-tolerated and biologically,active at all dose levels ...
Cached Medicine Technology:Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,at Society Of Nuclear Medicine 2007 Annual Meeting 2Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,at Society Of Nuclear Medicine 2007 Annual Meeting 3Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,at Society Of Nuclear Medicine 2007 Annual Meeting 4ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 2ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 3
Hand Drill, with two-position Handle, with Jacob three-jaw chuck, wrench-locked for changing twist drills up to 6 mm...
Hudson brace only. Component parts and accessories for Hudson cranial drill....
Width 3 (76 mm), length 6 3/4 (171 mm). Pattie Tray attaches to long or short arm....
Kit is supplied with four secondary bars. Secondary bars attach to primary bar. Length 12 (305 mm)....
Medicine Products: